Meeting
2023 ASCO Annual Meeting
Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness.
Authors
Amit Mahipal
UH Seidman Cancer Center, Case Western Reserve University, Cleveland, OH
Amit Mahipal , Julia C. F. Quintanilha , Ryon Graf , Michael H. Storandt , Rachel B Keller , Gerald Li , Jeffrey S. Ross , Richard S.P. Huang , Alexa Betzig Schrock , Geoffrey R. Oxnard , Sakti Chakrabarti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4146)
DOI
10.1200/JCO.2023.41.16_suppl.4146
Abstract #
4146
Poster Bd #
467
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Genomic profiling of prostate cancer at a diverse academic center.
First Author: Robert Lopez
Poster
2019 Gastrointestinal Cancers Symposium
The impact of CDKN2A mutations on overall survival in pancreatic adenocarcinoma.
First Author: Allison Doyle
Poster
2016 ASCO Annual Meeting
Assessment of tumor mutation burden from >60,000 clinical cancer patients using comprehensive genomic profiling.
First Author: Garrett Michael Frampton
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.
First Author: Elias Chandran